Matthew W Towse insider trades: NxStage Medical (NXTM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 20, 2017 | NXTM | ↓ Sell | 4,030 | $27.50 | $111K | Direct | Oct 23, 2017 (3d) |
| Sep 20, 2017 | NXTM | ↓ Sell | 4,300 | $27.27 | $117K | Direct | Sep 21, 2017 (1d) |
| Aug 21, 2017 | NXTM | ↓ Sell | 4,300 | $29.22 | $126K | Direct | Aug 23, 2017 (2d) |
| Jul 20, 2017 | NXTM | ↓ Sell | 4,300 | $24.16 | $104K | Direct | Jul 21, 2017 (1d) |
| Jun 20, 2017 | NXTM | ↓ Sell | 4,300 | $23.29 | $100K | Direct | Jun 21, 2017 (1d) |
| May 22, 2017 | NXTM | ↓ Sell | 4,300 | $21.36 | $92K | Direct | May 23, 2017 (1d) |
| Apr 20, 2017 | NXTM | ↓ Sell | 4,300 | $27.28 | $117K | Direct | Apr 20, 2017 (0d) |
| Mar 20, 2017 | NXTM | ↓ Sell | 4,300 | $27.66 | $119K | Direct | Mar 22, 2017 (2d) |
| Feb 21, 2017 | NXTM | ↓ Sell | 4,300 | $29.26 | $126K | Direct | Feb 23, 2017 (2d) |
| Jan 20, 2017 | NXTM | ↓ Sell | 4,300 | $26.19 | $113K | Direct | Jan 23, 2017 (3d) |
| Dec 20, 2016 | NXTM | ↓ Sell | 4,300 | $25.55 | $110K | Direct | Dec 20, 2016 (0d) |
| Nov 21, 2016 | NXTM | ↓ Sell | 4,300 | $26.23 | $113K | Direct | Nov 21, 2016 (0d) |
| Jan 11, 2016 | NXTM | ↓ Sell | 3,472 | $20.40 | $71K | Direct | Jan 11, 2016 (0d) |
| Dec 15, 2015 | NXTM | ↓ Sell | 2,863 | $19.51 | $56K | Direct | Dec 17, 2015 (2d) |
| Nov 10, 2015 | NXTM | ↓ Sell | 2,863 | $20.32 | $58K | Direct | Nov 12, 2015 (2d) |
| Nov 4, 2015 | NXTM | ↓ Sell | 8,591 | $19.50 | $168K | Direct | Nov 4, 2015 (0d) |
| Aug 6, 2015 | NXTM | ↓ Sell | 5,455 | $15.52 | $85K | Direct | Aug 10, 2015 (4d) |
| Jul 16, 2014 | NXTM | ↓ Sell | 228 | $13.44 | $3K | Direct | Jul 22, 2014 (6d) |
| May 5, 2005 | NYSE: | ↓ Sell | 292 | $13.94 | $4K | Direct | May 6, 2005 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Matthew W Towse's insider trades
Matthew W Towse is SVP and Chief Financial Office at NxStage Medical (NXTM). Since May 5, 2005, Matthew has reported no open-market purchases and 19 sales worth $1.8M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include option exercises (21 filings), grants and awards (7 filings), shares withheld for taxes (7 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every NXTM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.